

Memantine: a NMDA receptor antagonist that improves homeostasis in the glutamatergic system - too little activity worse

Neuropharmacology

53, 699-723

DOI: [10.1016/j.neuropharm.2007.07.013](https://doi.org/10.1016/j.neuropharm.2007.07.013)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Advances on the Understanding of the Origins of Synaptic Pathology in AD. <i>Current Genomics</i> , 2007, 8, 486-508.	0.7	32
2	Acute treatment with low doses of memantine does not impair aversive, non-associative and recognition memory in rats. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 376, 295-300.	1.4	26
3	Metabotropic glutamate receptor modulation, translational methods, and biomarkers: relationships with anxiety. <i>Psychopharmacology</i> , 2008, 199, 389-402.	1.5	33
4	A novel procedure for assessing the effects of drugs on satiation in baboons: effects of memantine and dexfenfluramine. <i>Psychopharmacology</i> , 2008, 199, 583-592.	1.5	10
5	The fraction of activated N-methyl-d-Aspartate receptors during synaptic transmission remains constant in the presence of the glutamate release inhibitor riluzole. <i>Journal of Neural Transmission</i> , 2008, 115, 1119-1126.	1.4	12
6	Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 6156-6160.	1.0	28
7	Amino acids in the brain: serine in neurotransmission and neurodegeneration. <i>FEBS Journal</i> , 2008, 275, 3514-3526.	2.2	257
8	Memantine in the Preventive Treatment of Refractory Migraine. <i>Headache</i> , 2008, 48, 1337-1342.	1.8	88
9	Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A ₂ in cortical neurons. <i>Journal of Neurochemistry</i> , 2008, 106, 45-55.	2.1	249
10	The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats. <i>European Journal of Pharmacology</i> , 2008, 598, 57-63.	1.7	50
11	Non-dopaminergic treatments in development for Parkinson's disease. <i>Lancet Neurology</i> , The, 2008, 7, 927-938.	4.9	106
12	Serine signalling as a prominent determinant of neuronal-glia dialogue in the healthy and diseased brain. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 1872-1884.	1.6	39
13	Pharmacotherapeutic targets in Alzheimer's disease. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 61-86.	1.6	50
14	Blocking NMDA receptor signaling does not decrease hormonal counterregulation to hypoglycemia in humans. <i>Psychoneuroendocrinology</i> , 2008, 33, 1069-1076.	1.3	7
15	Endocrine regulation of cognition and neuroplasticity: Our pursuit to unveil the complex interaction between hormones, the brain, and behaviour.. <i>Canadian Journal of Experimental Psychology</i> , 2008, 62, 247-260.	0.7	109
16	Randomized, Placebo-Controlled, Crossover Trial of Memantine for Cognitive Changes with Corticosteroid Therapy. <i>Biological Psychiatry</i> , 2008, 64, 727-729.	0.7	25
17	Inhibition of Acetylcholinesterase, β -Amyloid Aggregation, and NMDA Receptors in Alzheimer's Disease: A Promising Direction for the Multi-target-Directed Ligands Gold Rush. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4381-4384.	2.9	184
18	Inflammation and aging: Can endocannabinoids help?. <i>Biomedicine and Pharmacotherapy</i> , 2008, 62, 212-217.	2.5	27

#	ARTICLE	IF	CITATIONS
19	Pharmacodynamics of Memantine: An Update. <i>Current Neuropharmacology</i> , 2008, 6, 55-78.	1.4	141
20	Neurological and Psychiatric Practitionersâ€™ Views on Alzheimerâ€™s Disease and Treatment Thereof. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 541-546.	0.7	16
21	Mechanism of CNS Drugs and their Combinations for Alzheimers Disease. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2008, 8, 241-248.	0.5	1
22	Nonspecific Interaction of Prefibrillar Amyloid Aggregates with Glutamatergic Receptors Results in Ca ²⁺ Increase in Primary Neuronal Cells. <i>Journal of Biological Chemistry</i> , 2008, 283, 29950-29960.	1.6	46
23	Glutamate receptor-mediated restoration of experience-dependent place field expansion plasticity in aged rats.. <i>Behavioral Neuroscience</i> , 2008, 122, 535-548.	0.6	27
24	Pooled Analyses on Cognitive Effects of Memantine in Patients with Moderate to Severe Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2008, 14, 193-199.	1.2	50
25	Therapeutically relevant plasma concentrations of memantine produce significant L-N-methyl-D-aspartate receptor occupation and do not impair learning in rats. <i>Behavioural Pharmacology</i> , 2008, 19, 724-734.	0.8	29
26	GABAA Receptor-Mediated Acceleration of Aging-Associated Memory Decline in APP/PS1 Mice and Its Pharmacological Treatment by Picrotoxin. <i>PLoS ONE</i> , 2008, 3, e3029.	1.1	89
27	Department of Biochemistry. , 0, , 98-99.		8
28	Update on the use of memantine in Alzheimer’s disease. <i>Neuropsychiatric Disease and Treatment</i> , 2009, 5, 237.	1.0	92
29	NMDA-gated ion channel research and its therapeutic potentials in neurodegenerative diseases: a review. <i>Journal of Receptor, Ligand and Channel Research</i> , 2009, Volume 2, 59-73.	0.7	4
30	Neramexane: a moderate-affinity NMDA receptor channel blocker: new prospects and indications. <i>Expert Review of Clinical Pharmacology</i> , 2009, 2, 231-238.	1.3	17
31	Mg ²⁺ Imparts NMDA Receptor Subtype Selectivity to the Alzheimer's Drug Memantine. <i>Journal of Neuroscience</i> , 2009, 29, 2774-2779.	1.7	222
32	Memantine for dementia in people with Down syndrome. <i>The Cochrane Library</i> , 2021, 2021, CD007657.	1.5	22
33	Altered Prefrontal Glutamateâ€“Glutamineâ€“ ¹³ -Aminobutyric Acid Levels and Relation to Low Cognitive Performance and Depressive Symptoms in Type 1 Diabetes Mellitus. <i>Archives of General Psychiatry</i> , 2009, 66, 878.	13.8	82
34	Anesthesia and Postoperative Cognitive Dysfunction (POCD). <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 1568-1579.	1.1	50
35	Renal NMDA receptors independently stimulate proximal reabsorption and glomerular filtration. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, F976-F982.	1.3	45
36	Effects of steroid hormones on neurogenesis in the hippocampus of the adult female rodent during the estrous cycle, pregnancy, lactation and aging. <i>Frontiers in Neuroendocrinology</i> , 2009, 30, 343-357.	2.5	265

#	ARTICLE	IF	CITATIONS
37	Memantine treatment reduces the expression of the K ⁺ /Cl ⁻ cotransporter KCC2 in the hippocampus and cerebral cortex, and attenuates behavioural responses mediated by GABAA receptor activation in mice. <i>Brain Research</i> , 2009, 1265, 75-79.	1.1	20
38	Memantine blocks sensitization to the rewarding effects of morphine. <i>Brain Research</i> , 2009, 1288, 95-104.	1.1	29
39	Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. <i>Annals of Neurology</i> , 2009, 65, 577-585.	2.8	181
40	Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 532-538.	1.3	65
41	Tacrine-Melatonin Hybrids as Multifunctional Agents for Alzheimer's Disease, with Cholinergic, Antioxidant, and Neuroprotective Properties. <i>ChemMedChem</i> , 2009, 4, 828-841.	1.6	154
43	Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. <i>Psychopharmacology</i> , 2009, 204, 61-71.	1.5	50
44	Memantine binding to a superficial site on NMDA receptors contributes to partial trapping. <i>Journal of Physiology</i> , 2009, 587, 4589-4604.	1.3	75
45	Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. <i>Nature Medicine</i> , 2009, 15, 1407-1413.	15.2	381
46	Two cases of discontinuation syndrome following cessation of memantine. <i>Geriatrics and Gerontology International</i> , 2009, 9, 203-205.	0.7	13
47	Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. <i>British Journal of Pharmacology</i> , 2009, 157, 1301-1317.	2.7	358
48	The effect of spiroadamantane substitution on the conformational preferences of N-Me pyrrolidine and N-Me piperidine: a description based on dynamic NMR spectroscopy and ab initio correlated calculations. <i>Tetrahedron</i> , 2009, 65, 9428-9435.	1.0	6
49	Dual- and Triple-Acting Agents for Treating Core and Co-morbid Symptoms of Major Depression: Novel Concepts, New Drugs. <i>Neurotherapeutics</i> , 2009, 6, 53-77.	2.1	177
50	NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 3456-3462.	1.4	37
51	Cloud-Point Extraction Combined with LC-MS for Analysis of Memantine in Rat Plasma. <i>Chromatographia</i> , 2009, 69, 837-842.	0.7	24
52	Reviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2009, 24, 95-121.	0.9	245
53	Memantine. <i>CNS Drugs</i> , 2009, 23, 881-897.	2.7	74
54	Current Hypotheses and Research Milestones in Alzheimer's Disease. , 2009, , .		4
55	A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia. <i>Neuropsychopharmacology</i> , 2009, 34, 1322-1329.	2.8	155

#	ARTICLE	IF	CITATIONS
56	The role of GSK3 in Alzheimer disease. <i>Brain Research Bulletin</i> , 2009, 80, 248-250.	1.4	64
57	The history of the pharmacology and cloning of ionotropic glutamate receptors and the development of idiosyncratic nomenclature. <i>Neuropharmacology</i> , 2009, 56, 6-21.	2.0	138
58	Mechanism of bis(7)-tacrine inhibition of GABA-activated current in cultured rat hippocampal neurons. <i>Neuropharmacology</i> , 2009, 57, 33-40.	2.0	5
59	Effects of Colostrinin on gene expression-transcriptomal network analysis. <i>International Immunopharmacology</i> , 2009, 9, 181-193.	1.7	11
60	Transient global ischemia in rat brain promotes different NMDA receptor regulation depending on the brain structure studied. <i>Neurochemistry International</i> , 2009, 54, 180-185.	1.9	29
61	Neuroprotective effect of alpha-asarone on spatial memory and nitric oxide levels in rats injected with amyloid- β (25-35). <i>Neuroscience Letters</i> , 2009, 453, 98-103.	1.0	86
62	<i>N</i> -methyl-D-aspartate-evoked adenosine and inosine release from neurons requires extracellular calcium This article is one of a selection of papers published in a special issue celebrating the 125th anniversary of the Faculty of Medicine at the University of Manitoba.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2009, 87, 850-858.	0.7	12
63	Memantine: a comprehensive review of safety and efficacy. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 89-109.	1.0	74
64	Neuroprotective effect of treatment with galantamine and choline alphoscerate on brain microanatomy in spontaneously hypertensive rats. <i>Journal of the Neurological Sciences</i> , 2009, 283, 187-194.	0.3	45
65	Memantine Therapy of Behavioral Symptoms in Community-Dwelling Patients with Moderate to Severe Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 164-172.	0.7	50
66	The serotonin 5-HT ₆ receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1073-1085.	1.4	66
67	Novel Neuroprotective Mechanisms of Memantine: Increase in Neurotrophic Factor Release from Astroglia and Anti-Inflammation by Preventing Microglial Activation. <i>Neuropsychopharmacology</i> , 2009, 34, 2344-2357.	2.8	148
68	MTDL Design Strategy in the Context of Alzheimers Disease: From Lipocrine to Memoquin and Beyond. <i>Current Pharmaceutical Design</i> , 2009, 15, 601-613.	0.9	75
69	Medical chemistry for brain function correction. <i>Herald of the Russian Academy of Sciences</i> , 2010, 80, 279-284.	0.2	1
70	A within-subject cognitive battery in the rat: differential effects of NMDA receptor antagonists. <i>Psychopharmacology</i> , 2010, 212, 227-242.	1.5	55
71	Synthesis and NMDA receptor affinity of fluorinated dioxadrol analogues. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 4095-4102.	1.4	9
72	Synthesis and SAR studies of chiral non-racemic dexodrol analogues as uncompetitive NMDA receptor antagonists. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 7855-7867.	1.4	44
73	In vivo evidence for functional NMDA receptor blockade by memantine in rat hippocampal neurons. <i>Journal of Neural Transmission</i> , 2010, 117, 1189-1194.	1.4	9

#	ARTICLE	IF	CITATIONS
74	Alzheimer's Disease Amyloid β -Protein and Synaptic Function. <i>NeuroMolecular Medicine</i> , 2010, 12, 13-26.	1.8	122
75	Regulation of Kv2.1 phosphorylation in an animal model of anoxia. <i>Neurobiology of Disease</i> , 2010, 38, 85-91.	2.1	12
76	Deramciclane improves object recognition in rats: Potential role of NMDA receptors. <i>Pharmacology Biochemistry and Behavior</i> , 2010, 94, 570-574.	1.3	12
77	Memantine improves memory for taste-avoidance learning in day-old chicks exposed to isolation stress. <i>Pharmacology Biochemistry and Behavior</i> , 2010, 95, 203-208.	1.3	7
78	Neurochemical biomarkers in the differential diagnosis of movement disorders. <i>Movement Disorders</i> , 2010, 25, 500-500.	2.2	4
79	TremAn: A tool for measuring tremor frequency from video sequences. <i>Movement Disorders</i> , 2010, 25, 504-506.	2.2	8
80	The use of smell identification tests in the diagnosis of Parkinson's disease in Brazil. <i>Movement Disorders</i> , 2010, 25, 510-511.	2.2	3
81	Psychogenic movement disorder after a venlafaxine-induced dystonia. <i>Movement Disorders</i> , 2010, 25, 506-507.	2.2	4
82	Mortality in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 507-508.	2.2	6
83	NMDA antagonist memantine improves levodopa-induced dyskinesias and α -Syn phenomena in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 508-510.	2.2	55
84	Sydenham's chorea in a girl with juvenile idiopathic arthritis treated with anti-TNF \pm therapy. <i>Movement Disorders</i> , 2010, 25, 511-514.	2.2	5
85	Psychogenic chorea associated with family history of Huntington disease. <i>Movement Disorders</i> , 2010, 25, 503-504.	2.2	20
86	Fragile X-associated tremor/ataxia syndrome (FXTAS) with myoclonus. <i>Movement Disorders</i> , 2010, 25, 514-516.	2.2	4
87	Stiff person syndrome as the initial manifestation of systemic lupus erythematosus. <i>Movement Disorders</i> , 2010, 25, 516-517.	2.2	14
88	Pregabalin in the treatment of neuropathic tremor following a motor axonal form of Guillain-Barré syndrome. <i>Movement Disorders</i> , 2010, 25, 517-519.	2.2	8
89	Ropinirole diminishes myoclonus and improves writing and postural balance in an ULD patient. <i>Movement Disorders</i> , 2010, 25, 520-521.	2.2	6
90	Identification of a de novo mutation in <i>SPG11</i> . <i>Movement Disorders</i> , 2010, 25, 501-503.	2.2	1
91	Chorea induced by antihistamine drugs. <i>Movement Disorders</i> , 2010, 25, 519-520.	2.2	7

#	ARTICLE	IF	CITATIONS
92	A series of structurally novel heterotricyclic 1- <i>α</i> -amino- β -hydroxy- γ -methyl-4- <i>α</i> -isoxazole- β -propionate receptor- β -selective antagonists. <i>British Journal of Pharmacology</i> , 2010, 160, 1417-1429.	2.7	22
93	Interleukin-6-type cytokines in neuroprotection and neuromodulation: oncostatin M, but not leukemia inhibitory factor, requires neuronal adenosine A ₁ receptor function. <i>Journal of Neurochemistry</i> , 2010, 114, 1667-1677.	2.1	32
94	Cocaine-induced neuroadaptations in glutamate transmission. <i>Annals of the New York Academy of Sciences</i> , 2010, 1187, 35-75.	1.8	186
95	Imaging genomics. <i>Current Opinion in Neurology</i> , 2010, 23, 368-373.	1.8	97
96	Neural protein synthesis during aging: effects on plasticity and memory. <i>Frontiers in Aging Neuroscience</i> , 2010, 2, .	1.7	26
97	Computational studies of NMDA receptors: differential effects of neuronal activity on efficacy of competitive and noncompetitive antagonists. <i>Open Access Bioinformatics</i> , 2010, 2, 113.	0.9	21
98	Allosteric Inhibitors of NMDA Receptor Functions. <i>Pharmaceuticals</i> , 2010, 3, 3240-3257.	1.7	6
99	Pathologically Activated Neuroprotection via Uncompetitive Blockade of N-Methyl-d-aspartate Receptors with Fast Off-rate by Novel Multifunctional Dimer Bis(propyl)-cognitin. <i>Journal of Biological Chemistry</i> , 2010, 285, 19947-19958.	1.6	32
100	Amyloid- β as a Modulator of Synaptic Plasticity. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 741-763.	1.2	225
101	Activation of Extrasynaptic, But Not Synaptic, NMDA Receptors Modifies Amyloid Precursor Protein Expression Pattern and Increases Amyloid- β Production. <i>Journal of Neuroscience</i> , 2010, 30, 15927-15942.	1.7	156
102	Tacrine Derivatives and Alzheimers Disease. <i>Current Medicinal Chemistry</i> , 2010, 17, 1825-1838.	1.2	208
103	Memantine Discontinuation and the Health Status of Nursing Home Residents With Alzheimer's Disease. <i>Journal of the American Medical Directors Association</i> , 2010, 11, 636-644.e1.	1.2	13
104	Effect of Memantine Treatment on Regional Cortical Metabolism in Alzheimer's Disease. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 606-614.	0.6	15
105	Genome-wide analysis reveals novel genes influencing temporal lobe structure with relevance to neurodegeneration in Alzheimer's disease. <i>NeuroImage</i> , 2010, 51, 542-554.	2.1	141
106	Assessment of Structurally Diverse Philanthotoxin Analogues for Inhibitory Activity on Ionotropic Glutamate Receptor Subtypes: Discovery of Nanomolar, Nonselective, and Use-Dependent Antagonists. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 7441-7451.	2.9	22
107	Novel <i>N</i> -methyl- <i>d</i> -aspartate receptor antagonists: a review of compounds patented since 2006. <i>Expert Opinion on Therapeutic Patents</i> , 2010, 20, 1683-1702.	2.4	31
108	Protective effect of systemic l-kynurenine and probenecid administration on behavioural and morphological alterations induced by toxic soluble amyloid beta (25-35) in rat hippocampus. <i>Behavioural Brain Research</i> , 2010, 210, 240-250.	1.2	46
109	The putative neurodegenerative links between depression and Alzheimer's disease. <i>Progress in Neurobiology</i> , 2010, 91, 362-375.	2.8	105

#	ARTICLE	IF	CITATIONS
110	Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice. <i>Neuron</i> , 2010, 65, 178-190.	3.8	448
111	Neurochemical basis for symptomatic treatment of Alzheimer's disease. <i>Neuropharmacology</i> , 2010, 59, 221-229.	2.0	94
112	Memantine ameliorates scopolamine-induced amnesia in chicks trained on taste-avoidance learning. <i>Neurobiology of Learning and Memory</i> , 2010, 93, 540-545.	1.0	12
113	Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. <i>Trends in Neurosciences</i> , 2010, 33, 513-523.	4.2	267
114	Current and emerging therapies for migraine prevention and treatment. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2010, 97, 789-809.	1.0	0
115	Beyond the Cholinergic Hypothesis: Do Current Drugs Work in Alzheimer's Disease?. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 235-245.	1.9	122
116	Neurotoxicity by microglia: Mechanisms and potential therapeutic strategy. <i>Clinical and Experimental Neuroimmunology</i> , 2010, 1, 12-21.	0.5	62
117	Memantine Improves Cognition and Reduces Alzheimer's-Like Neuropathology in Transgenic Mice. <i>American Journal of Pathology</i> , 2010, 176, 870-880.	1.9	188
118	Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases. , 2010, , .		87
119	A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2010, 11, 456-460.	2.3	101
120	Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1765-1771.	0.9	27
121	Managing Cognitive Dysfunction through the Continuum of Alzheimer's Disease. <i>CNS Drugs</i> , 2011, 25, 213-226.	2.7	37
122	Voxelwise gene-wide association study (vGeneWAS): Multivariate gene-based association testing in 731 elderly subjects. <i>NeuroImage</i> , 2011, 56, 1875-1891.	2.1	116
123	Effect of Memantine on Resting State Default Mode Network Activity in Alzheimer's Disease. <i>Drugs and Aging</i> , 2011, 28, 205-217.	1.3	57
124	A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. <i>Drug and Alcohol Dependence</i> , 2011, 119, e23-e29.	1.6	35
125	Pharmacological characterizations of memantine-induced disruption of prepulse inhibition of the acoustic startle response in mice: Involvement of dopamine D2 and 5-HT2A receptors. <i>Behavioural Brain Research</i> , 2011, 218, 165-173.	1.2	20
126	Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function. <i>Molecular and Cellular Neurosciences</i> , 2011, 48, 308-320.	1.0	164
127	Management of moderate to severe Alzheimer's disease: Focus on memantine. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2011, 50, 415-423.	0.5	21

#	ARTICLE	IF	CITATIONS
128	Protection against A β -mediated rapid disruption of synaptic plasticity and memory by memantine. <i>Neurobiology of Aging</i> , 2011, 32, 614-623.	1.5	65
129	Subchronic memantine administration on spatial learning, exploratory activity, and nest-building in an APP/PS1 mouse model of Alzheimer's disease. <i>Neuropharmacology</i> , 2011, 60, 930-936.	2.0	49
130	Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of A β -amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. <i>Neuropharmacology</i> , 2011, 60, 982-990.	2.0	141
131	Effects of memantine and donepezil on cortical and hippocampal acetylcholine levels and object recognition memory in rats. <i>Neuropharmacology</i> , 2011, 61, 891-899.	2.0	33
132	Cognitive Enhancers in Moderate to Severe Alzheimer's Disease. <i>Clinical Medicine Insights Therapeutics</i> , 2011, 3, CMT.S6344.	0.4	4
133	A Step Further Towards Multitarget Drugs for Alzheimer and Neuronal Vascular Diseases: Targeting the Cholinergic System, Amyloid- β Aggregation and Ca ²⁺ Dyshomeostasis. <i>Current Medicinal Chemistry</i> , 2011, 18, 552-576.	1.2	50
134	From understanding synaptic plasticity to the development of cognitive enhancers. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 1247-1256.	1.0	13
135	Proteolysis of calcineurin is increased in human hippocampus during mild cognitive impairment and is stimulated by oligomeric A β in primary cell culture. <i>Aging Cell</i> , 2011, 10, 103-113.	3.0	41
136	Administration of Memantine During Ethanol Withdrawal in Neonatal Rats: Effects on Long-Term Ethanol-Induced Motor Incoordination and Cerebellar Purkinje Cell Loss. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 355-364.	1.4	21
137	Quality of the Rating of Mini-Mental State Examination in a Well-Defined Population of French General Practitioners. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 2182-2184.	1.3	0
138	Does Memantine Improve the Gait of Individuals with Alzheimer's Disease?. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 2181-2182.	1.3	28
139	Effects of Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist, on Genomic Stability. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 109, 413-417.	1.2	17
140	The effects of a single memantine treatment on behavioral alterations associated with binge alcohol exposure in neonatal rats. <i>Neurotoxicology and Teratology</i> , 2011, 33, 444-450.	1.2	14
141	Neuroprotection against excitotoxic and ischemic insults by bis(12)-hupyrindone, a novel anti-acetylcholinesterase dimer, possibly via acting on multiple targets. <i>Brain Research</i> , 2011, 1421, 100-109.	1.1	13
142	D-amino acids in normal ageing and pathogenesis of neurodegenerative diseases. <i>Neurochemical Journal</i> , 2011, 5, 100-114.	0.2	19
143	Drug Therapy of Post-Stroke Aphasia: A Review of Current Evidence. <i>Neuropsychology Review</i> , 2011, 21, 302-317.	2.5	90
144	E-6801, a 5-HT ₆ receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. <i>Psychopharmacology</i> , 2011, 213, 413-430.	1.5	85
145	Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu _{2/3} receptor agonist. <i>Psychopharmacology</i> , 2011, 214, 505-514.	1.5	32

#	ARTICLE	IF	CITATIONS
146	A role for glutamate in subjective response to smoking and its action on inhibitory control. <i>Psychopharmacology</i> , 2011, 216, 29-42.	1.5	13
147	A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory. <i>Psychopharmacology</i> , 2011, 217, 255-269.	1.5	92
148	Progress in the development of new drugs in Alzheimer's disease. <i>Journal of Nutrition, Health and Aging</i> , 2011, 15, 45-57.	1.5	34
150	The effect of co-administration of the NMDA blocker with agonist and antagonist of CB1-receptor on penicillin-induced epileptiform activity in rats. <i>Epilepsy Research</i> , 2011, 93, 128-137.	0.8	27
151	Memantine: a treatment for Alzheimer's disease with a new formulation. <i>Aging Health</i> , 2011, 7, 349-362.	0.3	3
152	Activation of Brain Histaminergic Neurotransmission: A Mechanism for Cognitive Effects of Memantine in Alzheimer's Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 336, 479-487.	1.3	24
153	An Open-Label, Multicenter Observational Study for Patients with Alzheimer's Disease Treated with Memantine in the Clinical Practice. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2011, 1, 10-19.	0.6	2
154	On the Promise of Pharmacotherapies Targeted at Cognitive and Neurodegenerative Components of Down Syndrome. <i>Developmental Neuroscience</i> , 2011, 33, 414-427.	1.0	33
155	KCa2 channels activation prevents [Ca ²⁺] _i deregulation and reduces neuronal death following glutamate toxicity and cerebral ischemia. <i>Cell Death and Disease</i> , 2011, 2, e147-e147.	2.7	49
156	Can small molecules provide truly effective enhancement of cognition? Current achievements and future directions. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 795-811.	1.9	8
157	Abhorring the vacuum: use of Alzheimer's disease medications in frontotemporal dementia. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 709-717.	1.4	47
158	Synapses, NMDA receptor activity and neuronal A β production in Alzheimer's disease. <i>Reviews in the Neurosciences</i> , 2011, 22, 285-294.	1.4	63
159	Using an experimental medicine model to understand the antidepressant potential of the N-Methyl-D-aspartic acid (NMDA) receptor antagonist memantine. <i>Journal of Psychopharmacology</i> , 2012, 26, 1417-1423.	2.0	18
160	<i>Geriatric pharmacology.</i> , 2012, , 38-63.		0
161	Effectiveness of the Combination of Memantine Plus Vitamin D on Cognition in Patients With Alzheimer Disease. <i>Cognitive and Behavioral Neurology</i> , 2012, 25, 121-127.	0.5	91
162	Viral Encephalitis: Current Treatments and Future Perspectives. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2012, 12, 277-285.	0.5	2
163	Basic Pharmacology of NMDA Receptors. <i>Current Pharmaceutical Design</i> , 2012, 18, 1558-1567.	0.9	57
164	Screening of 64 Tryptamines at NMDA, 5-HT1A, and 5-HT2A Receptors: A Comparative Binding and Modeling Study. <i>Current Medicinal Chemistry</i> , 2012, 19, 3044-3057.	1.2	8

#	ARTICLE	IF	CITATIONS
165	Early Intervention Combined with Targeted Treatment Promotes Cognitive and Behavioral Improvements in Young Children with Fragile X Syndrome. <i>Case Reports in Genetics</i> , 2012, 2012, 1-4.	0.1	39
166	Development and Validation of Stability-Indicating GC-FID Method for the Quantitation of Memantine Hydrochloride and Its Nonchromophoric Impurities in Bulk and Pharmaceutical Dosages. <i>Chromatography Research International</i> , 2012, 2012, 1-10.	0.4	8
167	Analytical Method Development and Validation of Pharmaceutical Analysis Using Chromatographic Techniques. <i>Chromatography Research International</i> , 2012, 2012, 1-1.	0.4	9
168	NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease. <i>Current Neuropharmacology</i> , 2012, 10, 272-285.	1.4	75
170	Alzheimer's disease, β -amyloid, glutamate, NMDA receptors and memantine – searching for the connections. <i>British Journal of Pharmacology</i> , 2012, 167, 324-352.	2.7	396
171	Cognitive Enhancers (Nootropics). Part 1: Drugs Interacting with Receptors. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 793-887.	1.2	67
172	Design and Synthesis of Skeletal Analogues of Gambierol: Attenuation of Amyloid- β and Tau Pathology with Voltage-Gated Potassium Channel and <i>N</i> -Methyl-D-aspartate Receptor Implications. <i>Journal of the American Chemical Society</i> , 2012, 134, 7467-7479.	6.6	62
173	Memantine facilitates memory consolidation and reconsolidation in the day-old chick. <i>Neurobiology of Learning and Memory</i> , 2012, 97, 380-385.	1.0	13
174	Influence of external magnesium ions on the NMDA receptor channel block by different types of organic cations. <i>Neuropharmacology</i> , 2012, 62, 2078-2085.	2.0	54
175	Agmatine protects against scopolamine-induced water maze performance impairment and hippocampal ERK and Akt inactivation. <i>Neuropharmacology</i> , 2012, 62, 2018-2023.	2.0	65
176	Memantine potentiates hippocampal theta oscillations at a therapeutic dose in anesthetized mice: A mechanistic link to its cognitive-enhancing properties. <i>Neuropharmacology</i> , 2012, 62, 2208-2218.	2.0	24
177	Targeting Synaptic Dysfunction in Alzheimer's Disease Therapy. <i>Molecular Neurobiology</i> , 2012, 46, 572-587.	1.9	80
178	Endoplasmic reticulum stress occurs downstream of GluN2B subunit of <i>N</i> -methyl-D-aspartate receptor in mature hippocampal cultures treated with amyloid- β oligomers. <i>Aging Cell</i> , 2012, 11, 823-833.	3.0	100
179	Cognitive enhancing effects of an AMPA receptor positive modulator on place learning in mice. <i>Behavioural Brain Research</i> , 2012, 226, 18-25.	1.2	6
180	Memantine partly rescues behavioral and cognitive deficits in an animal model of neurodegeneration. <i>Neuropharmacology</i> , 2012, 62, 2010-2017.	2.0	31
181	Memantine combined with environmental enrichment improves spatial memory and alleviates Alzheimer's disease-like pathology in senescence-accelerated prone-8 (SAMP8) mice. <i>Journal of Biomedical Research</i> , 2012, 26, 439.	0.7	16
182	Stabilizers of Neuronal and Mitochondrial Calcium Cycling as a Strategy for Developing a Medicine for Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2012, 3, 873-883.	1.7	33
183	Functions of connexins and large pore channels on microglial cells: The gates to environment. <i>Brain Research</i> , 2012, 1487, 16-24.	1.1	14

#	ARTICLE	IF	CITATIONS
184	Increasing power for voxel-wise genome-wide association studies: The random field theory, least square kernel machines and fast permutation procedures. <i>NeuroImage</i> , 2012, 63, 858-873.	2.1	76
185	Possibility of a New Anti-Alzheimer's Disease Pharmaceutical Composition Combining Memantine and Vitamin D. <i>Drugs and Aging</i> , 2012, 29, 81-91.	1.3	35
186	Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1351-1365.	1.4	39
187	Metal Chaperones: A Holistic Approach to the Treatment of Alzheimer's Disease. <i>Frontiers in Psychiatry</i> , 2012, 3, 15.	1.3	20
188	Selective Impairment of Some Forms of Synaptic Plasticity by Oligomeric Amyloid- β^2 Peptide in the Mouse Hippocampus: Implication of Extrasynaptic NMDA Receptors. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 183-196.	1.2	37
189	The essential role of AMPA receptor GluR2 subunit RNA editing in the normal and diseased brain. <i>Frontiers in Molecular Neuroscience</i> , 2012, 5, 34.	1.4	170
190	Effects of positive modulators of α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors in a benzodiazepine-induced deficit of spatial discrimination in mice. <i>Journal of Psychopharmacology</i> , 2012, 26, 845-856.	2.0	5
191	Synthesis of benzopolycyclic cage amines: NMDA receptor antagonist, trypanocidal and antiviral activities. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 942-948.	1.4	17
192	1-Benzyl-1,2,3,4-Tetrahydro- β -Carboline as Channel Blocker of NMDA Receptors. <i>Chemical Biology and Drug Design</i> , 2012, 79, 594-599.	1.5	16
193	Roles of glutamate signaling in preclinical and/or mechanistic models of depression. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 100, 688-704.	1.3	89
194	Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: Focus on pharmacology and preclinical translational models. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 100, 775-800.	1.3	73
195	A New Appraisal of Combined Treatments for PTSD in the Era of Psychotherapy Adjunctive Medications. <i>Journal of Contemporary Psychotherapy</i> , 2012, 42, 69-76.	0.7	4
196	Short-term development of behavioral sensitization to amphetamine requires NMDA and nicotinic-dependent mechanisms in the nucleus accumbens. <i>Addiction Biology</i> , 2013, 18, 417-424.	1.4	10
197	Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease. <i>Medicinal Research Reviews</i> , 2013, 33, 139-189.	5.0	394
198	Subchronic memantine induced concurrent functional disconnectivity and altered ultra-structural tissue integrity in the rodent brain: revealed by multimodal MRI. <i>Psychopharmacology</i> , 2013, 227, 479-491.	1.5	18
199	Hippocampal Glutamate Level and Glutamate Aspartate Transporter (GLAST) are Up-Regulated in Senior Rat Associated with Isoflurane-Induced Spatial Learning/Memory Impairment. <i>Neurochemical Research</i> , 2013, 38, 59-73.	1.6	34
200	The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 45, 242-249.	2.5	24
201	Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer's Disease. <i>Neurotoxicity Research</i> , 2013, 24, 358-369.	1.3	246

#	ARTICLE	IF	CITATIONS
202	NMDA-receptor inhibition increases spine stability of denervated mouse dentate granule cells and accelerates spine density recovery following entorhinal denervation in vitro. <i>Neurobiology of Disease</i> , 2013, 59, 267-276.	2.1	31
203	Comparison of behavioral effects of the NMDA receptor channel blockers memantine and ketamine in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 109, 67-76.	1.3	31
204	Synthesis of phenylalaninol-derived oxazolopyrrolidone lactams and evaluation as NMDA receptor antagonists. <i>Monatshefte für Chemie</i> , 2013, 144, 473-477.	0.9	13
205	Evaluation of neurotransmitters involved in the anxiolytic and panicolytic effect of the aqueous fraction of <i>Paullinia cupana</i> (guaraná) in elevated T maze. <i>Revista Brasileira De Farmacognosia</i> , 2013, 23, 358-365.	0.6	13
206	Effects of group II and III metabotropic glutamate receptor ligands on conditioned taste aversion learning. <i>Behavioural Brain Research</i> , 2013, 253, 9-16.	1.2	7
207	Role of nonsynaptic GluN2B-containing NMDA receptors in excitotoxicity: Evidence that fluoxetine selectively inhibits these receptors and may have neuroprotective effects. <i>Brain Research Bulletin</i> , 2013, 93, 32-38.	1.4	107
208	Slow Excitotoxicity in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 643-668.	1.2	82
209	Preparation and testing of homocubyl amines as therapeutic NMDA receptor antagonists. <i>Medicinal Chemistry Research</i> , 2013, 22, 360-366.	1.1	25
210	Memantine block depends on agonist presentation at the NMDA receptor in substantia nigra pars compacta dopamine neurones. <i>Neuropharmacology</i> , 2013, 73, 138-146.	2.0	23
211	Key Binding Interactions for Memantine in the NMDA Receptor. <i>ACS Chemical Neuroscience</i> , 2013, 4, 255-260.	1.7	41
212	Nicotinic Acetylcholine Receptors Contribute to Learning-induced Metaplasticity in the Hippocampus. <i>Journal of Cognitive Neuroscience</i> , 2013, 25, 986-997.	1.1	13
213	The Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives. <i>Chemical Reviews</i> , 2013, 113, 3516-3604.	23.0	517
214	Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer's Disease. <i>Clinical Pharmacokinetics</i> , 2013, 52, 225-241.	1.6	156
215	Structure-Activity Relationship Studies of Argiotoxins: Selective and Potent Inhibitors of Ionotropic Glutamate Receptors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 1171-1181.	2.9	29
216	Memantine protects cholinergic and glutamatergic septal neurons from A β ²¹⁻⁴⁰ -induced toxicity. <i>Neuroscience Letters</i> , 2013, 541, 54-57.	1.0	10
217	Emerging roles of metaplasticity in behaviour and disease. <i>Trends in Neurosciences</i> , 2013, 36, 353-362.	4.2	164
218	Amyloid β , Glutamate, Excitotoxicity in Alzheimer's Disease: Are We on the Right Track?. <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 549-555.	1.9	159
219	NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. <i>Nature Reviews Neuroscience</i> , 2013, 14, 383-400.	4.9	1,928

#	ARTICLE	IF	CITATIONS
220	4-Hydroxybenzyl Alcohol Confers Neuroprotection Through Up-Regulation of Antioxidant Protein Expression. <i>Neurochemical Research</i> , 2013, 38, 1501-1516.	1.6	26
221	NMDA receptors and memory encoding. <i>Neuropharmacology</i> , 2013, 74, 32-40.	2.0	228
222	Psychoneurochemical Investigations to Reveal Neurobiology of Memory Deficit in Epilepsy. <i>Neurochemical Research</i> , 2013, 38, 2503-2515.	1.6	30
223	A Meta-Analysis of the Efficacy of Donepezil, Rivastigmine, Galantamine, and Memantine in Relation to Severity of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 349-361.	1.2	136
224	Memantine Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 336-342.	0.7	48
225	Roles of glial cells in neuroinflammation and neurodegeneration. <i>Clinical and Experimental Neuroimmunology</i> , 2013, 4, 2-16.	0.5	22
226	Low-dose lamotrigine augmentation therapy improves residual symptoms in treatment-resistant schizophrenia: A report of five cases. <i>Asia-Pacific Psychiatry</i> , 2013, 5, 336-343.	1.2	4
227	Microglia and Glutamate. <i>Advances in Neuroimmune Biology</i> , 2013, 4, 77-83.	0.7	2
228	Rehabilitation and pharmacotherapy of cognitive impairments. , 0, , 511-542.		1
229	Selective Pharmacological Modulation of Pyramidal Neurons and Interneurons in the CA1 Region of the Rat Hippocampus. <i>Frontiers in Pharmacology</i> , 2013, 4, 24.	1.6	15
230	Differential Pharmacological Effects on Brain Reactivity and Plasticity in Alzheimer's Disease. <i>Frontiers in Psychiatry</i> , 2013, 4, 124.	1.3	20
231	Low-dose memantine-induced working memory improvement in the allothetic place avoidance alternation task (APAAT) in young adult male rats. <i>Frontiers in Behavioral Neuroscience</i> , 2013, 7, 203.	1.0	14
232	Safety and Efficacy of Memantine Extended-Release in the Management of Alzheimer's Disease. <i>Clinical Medicine Insights Therapeutics</i> , 2013, 5, CMT.S7794.	0.4	0
233	Potential Therapeutic Strategies to Prevent the Progression of Alzheimer to Disease States. , 0, , .		2
234	Applying pharmacology to practice: The case of dementia. <i>NursePrescribing</i> , 2013, 11, 185-190.	0.1	6
235	Humanin Rescues Cultured Rat Cortical Neurons from NMDA-Induced Toxicity Not by NMDA Receptor. <i>Scientific World Journal</i> , The, 2014, 2014, 1-8.	0.8	14
236	D-Serine in Neuropsychiatric Disorders: New Advances. <i>Advances in Psychiatry</i> , 2014, 2014, 1-16.	0.4	17
237	Gap junctions and hemichannels composed of connexins: potential therapeutic targets for neurodegenerative diseases. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 189.	1.8	108

#	ARTICLE	IF	CITATIONS
238	The Glutamatergic Hypothesis for Down Syndrome: The Potential Use of N-Methyl-D-Aspartate Receptor Antagonists to Enhance Cognition and Decelerate Neurodegeneration. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 16-25.	0.8	14
239	Glutamatergic Transmission Aberration: A Major Cause of Behavioral Deficits in a Murine Model of Down's Syndrome. <i>Journal of Neuroscience</i> , 2014, 34, 5099-5106.	1.7	45
240	The Role of Glycogen Synthase Kinase 3 in the Mechanisms of Learning and Memory. <i>Neuroscience and Behavioral Physiology</i> , 2014, 44, 1051-1058.	0.2	1
241	The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development. <i>Current Medicinal Chemistry</i> , 2014, 21, 3551-3575.	1.2	132
242	Methyllycaconitine and scopolamine induced cognitive dysfunction: differential reversal effect by cognition-enhancing drugs. <i>Pharmacology Research and Perspectives</i> , 2014, 2, e00048.	1.1	27
243	Effectiveness of Amantadine Hydrochloride in the Reduction of Chronic Traumatic Brain Injury Irritability and Aggression. <i>Journal of Head Trauma Rehabilitation</i> , 2014, 29, 391-399.	1.0	78
244	Tackling Negative Symptoms of Schizophrenia with Memantine. <i>Case Reports in Psychiatry</i> , 2014, 2014, 1-3.	0.2	7
245	Administration of Memantine During Withdrawal Mitigates Overactivity and Spatial Learning Impairments Associated with Neonatal Alcohol Exposure in Rats. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 529-537.	1.4	18
246	Concomitant manipulation of murine NMDA- and AMPA-receptors to produce pro-cognitive drug effects in mice. <i>European Neuropsychopharmacology</i> , 2014, 24, 309-320.	0.3	17
247	Effects of the 5-HT _{2C} receptor agonist meta-chlorophenylpiperazine on appetite, food intake and emotional processing in healthy volunteers. <i>Psychopharmacology</i> , 2014, 231, 2449-2459.	1.5	23
248	Physical exercise improves synaptic dysfunction and recovers the loss of survival factors in 3xTg-AD mouse brain. <i>Neuropharmacology</i> , 2014, 81, 55-63.	2.0	114
249	Multi-target Design Strategies in the Context of Alzheimer's Disease: Acetylcholinesterase Inhibition and NMDA Receptor Antagonism as the Driving Forces. <i>Neurochemical Research</i> , 2014, 39, 1914-1923.	1.6	80
250	Neuroplasticity, neurotransmitters and new directions for treatment of anomia in Alzheimer disease. <i>Aphasiology</i> , 2014, 28, 219-235.	1.4	5
251	Effects of memantine treatment on language abilities and functional communication: A review of data. <i>Aphasiology</i> , 2014, 28, 236-257.	1.4	12
252	Changes in Gait Variability with Anti-dementia Drugs: A Systematic Review and Meta-analysis. <i>CNS Drugs</i> , 2014, 28, 513-518.	2.7	19
253	Glutamatergic Dysfunctioning in Alzheimer's Disease and Related Therapeutic Targets. <i>Journal of Alzheimer's Disease</i> , 2014, 42, S177-S187.	1.2	64
254	Synaptic plasticity in glutamatergic and GABAergic neurotransmission following chronic memantine treatment in an in vitro model of limbic epileptogenesis. <i>Neuropharmacology</i> , 2014, 77, 379-386.	2.0	15
255	The potential role of kynurenines in Alzheimer's disease: pathomechanism and therapeutic possibilities by influencing the glutamate receptors. <i>Journal of Neural Transmission</i> , 2014, 121, 881-889.	1.4	18

#	ARTICLE	IF	CITATIONS
256	Novel Treatment with Neuroprotective and Antiviral Properties against a Neuroinvasive Human Respiratory Virus. <i>Journal of Virology</i> , 2014, 88, 1548-1563.	1.5	50
257	Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: Relevance to schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 54, 299-314.	2.5	17
258	Glutamate metabolism and HIV-associated neurocognitive disorders. <i>Journal of NeuroVirology</i> , 2014, 20, 315-331.	1.0	53
259	Protective action of glutamate antibodies on increased expression of genes of programmed death of rat brain cells induced by injection of a β -amyloid fragment (25-35). <i>Biology Bulletin</i> , 2014, 41, 118-125.	0.1	3
260	Combination of memantine and vitamin D prevents axon degeneration induced by amyloid-beta and glutamate. <i>Neurobiology of Aging</i> , 2014, 35, 331-335.	1.5	53
261	Gait Changes with Anti-Dementia Drugs: A Prospective, Open-Label Study Combining Single and Dual Task Assessments in Patients with Alzheimer's Disease. <i>Drugs and Aging</i> , 2014, 31, 363-372.	1.3	22
262	Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 913-925.	0.9	27
263	Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia. <i>Schizophrenia Research</i> , 2014, 157, 84-89.	1.1	50
264	Differential effects of NMDA receptor antagonists at lower and higher doses on basal gamma band oscillation power in rat cortical electroencephalograms. <i>Neuropharmacology</i> , 2014, 85, 384-396.	2.0	56
265	Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged <i>Octodon degus</i> . <i>Neuropharmacology</i> , 2014, 85, 206-214.	2.0	21
266	Memantine prevents memory consolidation failure induced by soluble beta amyloid in rats. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 332.	1.0	38
267	Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease. <i>Scientific Reports</i> , 2015, 5, 14781.	1.6	47
269	Memantine improves observational learning in day-old chicks. <i>Behavioural Pharmacology</i> , 2015, 26, 407-410.	0.8	4
270	A Review on GABA/Glutamate Pathway for Therapeutic Intervention of ASD and ADHD. <i>Current Medicinal Chemistry</i> , 2015, 22, 1850-1859.	1.2	47
271	Drug therapy and disease management: An opinion. <i>Archives of Medical and Biomedical Research</i> , 2015, 1, 163.	0.2	0
272	Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease. <i>International Journal of Nanomedicine</i> , 2015, 10, 4981.	3.3	211
273	NMDA Receptor Function During Senescence: Implication on Cognitive Performance. <i>Frontiers in Neuroscience</i> , 2015, 9, 473.	1.4	95
274	Altered Neurotransmission Prior to Cognitive Decline in β APP/PS1 Mice, a Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 771-776.	1.2	40

#	ARTICLE	IF	CITATIONS
275	Combination effect of memantine and mesenchymal stem cells on the recovery of brain damage in a rat model of brain ischemia. <i>Animal Cells and Systems</i> , 2015, 19, 110-118.	0.8	1
276	Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 28.	3.0	57
277	MRZ-99030 – A novel modulator of A β aggregation: II – Reversal of A β oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice. <i>Neuropharmacology</i> , 2015, 92, 170-182.	2.0	23
278	Anemoside A3 Enhances Cognition through the Regulation of Synaptic Function and Neuroprotection. <i>Neuropsychopharmacology</i> , 2015, 40, 1877-1887.	2.8	23
279	Identification of novel allosteric modulator binding sites in NMDA receptors: A molecular modeling study. <i>Journal of Molecular Graphics and Modelling</i> , 2015, 61, 204-213.	1.3	3
280	Effects of memantine on hippocampal long-term potentiation, gamma activity, and sensorimotor gating in freely moving rats. <i>Neurobiology of Aging</i> , 2015, 36, 2544-2554.	1.5	14
281	Bilateral brain reorganization with memantine and constraint-induced aphasia therapy in chronic post-stroke aphasia: An ERP study. <i>Brain and Language</i> , 2015, 145-146, 1-10.	0.8	38
282	1,2-Naphthoquinone-4-sulfonic acid sodium salt as a reagent for spectrophotometric determination of rimantadine and memantine. <i>Journal of Analytical Chemistry</i> , 2015, 70, 320-327.	0.4	7
283	Loss of F-box Only Protein 2 (Fbxo2) Disrupts Levels and Localization of Select NMDA Receptor Subunits, and Promotes Aberrant Synaptic Connectivity. <i>Journal of Neuroscience</i> , 2015, 35, 6165-6178.	1.7	36
284	The Role of the Tripartite Glutamatergic Synapse in the Pathophysiology of Alzheimer's Disease. , 2015, 6, 131.		114
285	Low-dose add-on memantine treatment may improve cognitive performance and self-reported health conditions in opioid-dependent patients undergoing methadone-maintenance-therapy. <i>Scientific Reports</i> , 2015, 5, 9708.	1.6	8
286	Dinitrobenzene sulphonic acid-induced colitis impairs spatial recognition memory in mice: roles of N-methyl D-aspartate receptors and nitric oxide. <i>Psychopharmacology</i> , 2015, 232, 3081-3090.	1.5	7
288	Infection, systemic inflammation, and Alzheimer's disease. <i>Microbes and Infection</i> , 2015, 17, 549-556.	1.0	81
289	Oxidative stress involving changes in Nrf2 and ER stress in early stages of Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 1428-1441.	1.8	137
290	Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil. <i>Experimental Gerontology</i> , 2015, 72, 109-116.	1.2	15
291	Memantine Augmentation in a Down's Syndrome Adolescent with Treatment- Resistant Obsessive-Compulsive Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 593-595.	0.7	5
292	The Dichotomy of Memantine Treatment for Ischemic Stroke: Dose-Dependent Protective and Detrimental Effects. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 230-239.	2.4	46
293	Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 123-133.	1.5	30

#	ARTICLE	IF	CITATIONS
294	Recent insights into the mode of action of memantine and ketamine. <i>Current Opinion in Pharmacology</i> , 2015, 20, 54-63.	1.7	79
295	Developmental Expression of N-Methyl-d-Aspartate (NMDA) Receptor Subunits in Human White and Gray Matter: Potential Mechanism of Increased Vulnerability in the Immature Brain. <i>Cerebral Cortex</i> , 2015, 25, 482-495.	1.6	85
296	The Role of Cysteine Protease in Alzheimer Disease. <i>Materia Socio-medica</i> , 2016, 28, 235.	0.3	25
297	Effects of thymoquinone, the major constituent of <i>Nigella sativa</i> seeds, on penicillin-induced epileptiform activity in rats. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2016, 21, 131-137.	0.5	19
298	Therapeutic Approach of a High Functioning Individual With Traumatic Brain Injury and Subsequent Emotional Volatility With Features of Pathological Laughter and Crying With Dextromethorphan/Quinidine. <i>Medicine (United States)</i> , 2016, 95, e2886.	0.4	9
299	Tonically active NMDA receptors – a signalling mechanism critical for interneuronal excitability in the CA1 stratum radiatum. <i>European Journal of Neuroscience</i> , 2016, 43, 169-178.	1.2	31
300	Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. , 2016, 164, 170-182.		125
301	A multipronged, nutritional-based strategy for managing Alzheimer's disease. <i>Medical Hypotheses</i> , 2016, 91, 98-102.	0.8	3
302	The emerging role of in vitro electrophysiological methods in CNS safety pharmacology. <i>Journal of Pharmacological and Toxicological Methods</i> , 2016, 81, 47-59.	0.3	43
303	Memantine improves memory impairment and depressive-like behavior induced by amphetamine withdrawal in rats. <i>Brain Research</i> , 2016, 1642, 389-396.	1.1	12
304	Recent progress in multifunctional metal chelators as potential drugs for Alzheimer's disease. <i>Coordination Chemistry Reviews</i> , 2016, 327-328, 287-303.	9.5	106
305	Synaptic pathology: A shared mechanism in neurological disease. <i>Ageing Research Reviews</i> , 2016, 28, 72-84.	5.0	122
306	MK-801 and memantine act differently on short-term memory tested with different time-intervals in the Morris water maze test. <i>Behavioural Brain Research</i> , 2016, 311, 15-23.	1.2	8
307	Using crystal structure prediction to rationalize the hydration propensities of substituted adamantane hydrochloride salts. <i>Acta Crystallographica Section B: Structural Science, Crystal Engineering and Materials</i> , 2016, 72, 551-561.	0.5	15
308	Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12304-12309.	3.3	129
309	The combination of memantine and galantamine improves cognition in rats: The synergistic role of the $\alpha 7$ nicotinic acetylcholine and NMDA receptors. <i>Behavioural Brain Research</i> , 2016, 313, 214-218.	1.2	43
310	Effects of memantine on the excitation-inhibition balance in prefrontal cortex. <i>Neurobiology of Disease</i> , 2016, 96, 75-83.	2.1	36
311	Treatment strategies in Alzheimer's disease: a review with focus on selenium supplementation. <i>BioMetals</i> , 2016, 29, 827-839.	1.8	56

#	ARTICLE	IF	CITATIONS
312	Mechanistic Insight into NMDA Receptor Dysregulation by Rare Variants in the GluN2A and GluN2B Agonist Binding Domains. <i>American Journal of Human Genetics</i> , 2016, 99, 1261-1280.	2.6	158
313	Recent progress in repositioning Alzheimer's disease drugs based on a multitarget strategy. <i>Future Medicinal Chemistry</i> , 2016, 8, 2113-2142.	1.1	61
314	Effects of (γ)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with L-DOPA. <i>Neuroscience</i> , 2016, 339, 644-654.	1.1	21
315	Extrasynaptic NMDA receptor-induced tau overexpression mediates neuronal death through suppressing survival signaling ERK phosphorylation. <i>Cell Death and Disease</i> , 2016, 7, e2449-e2449.	2.7	51
316	Amelioration of scopolamine-induced amnesia by phosphatidylserine and curcumin in the day-old chick. <i>Behavioural Pharmacology</i> , 2016, 27, 536-541.	0.8	5
317	Combined treatment with pantothenic acid derivatives and memantine alleviates scopolamine-induced amnesia in rats: The involvement of the thiol redox state and coenzyme A. <i>Neurochemical Journal</i> , 2016, 10, 120-130.	0.2	4
318	Memantine alters striatal plasticity inducing a shift of synaptic responses toward long-term depression. <i>Neuropharmacology</i> , 2016, 101, 341-350.	2.0	16
319	Practical Pharmacology for Alzheimer's Disease. , 2016, , .		2
320	Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders. , 2016, 159, 1-22.		84
321	A new simultaneous derivatization and microextraction method for the determination of memantine hydrochloride in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1008, 26-31.	1.2	11
322	Memantine (Generic and Namenda XR). , 2016, , 174-180.		0
323	Post-acute delivery of memantine promotes post-ischemic neurological recovery, peri-infarct tissue remodeling, and contralesional brain plasticity. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 980-993.	2.4	41
324	A Perspective on <i>Crocus sativus</i> L. (Saffron) Constituent Crocin: A Potent Water-Soluble Antioxidant and Potential Therapy for Alzheimer's Disease. <i>Journal of Agricultural and Food Chemistry</i> , 2017, 65, 1005-1020.	2.4	120
325	Optimization of Bicyclic Lactam Derivatives as NMDA Receptor Antagonists. <i>ChemMedChem</i> , 2017, 12, 537-545.	1.6	5
326	Therapeutics of Neurotransmitters in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 1049-1069.	1.2	169
327	Combined Memantine and Donepezil Treatment Improves Behavioral and Psychological Symptoms of Dementia-Like Behaviors in Olfactory Bulbectomized Mice. <i>Pharmacology</i> , 2017, 99, 160-171.	0.9	17
328	Involvement of GluN2B subunit containing N-methyl- d -aspartate (NMDA) receptors in mediating the acute and chronic synaptotoxic effects of oligomeric amyloid-beta ($A\beta^2$) in murine models of Alzheimer's disease (AD). <i>Neuropharmacology</i> , 2017, 123, 100-115.	2.0	29
329	Alterations in expression of Cat α 315 epitope of perineuronal nets during normal ageing, and its modulation by an open-channel NMDA receptor blocker, memantine. <i>Journal of Comparative Neurology</i> , 2017, 525, 2035-2049.	0.9	15

#	ARTICLE	IF	CITATIONS
330	Spatial recognition test: A novel cognition task for assessing topographical memory in mice. <i>Journal of Psychopharmacology</i> , 2017, 31, 653-659.	2.0	1
331	Pharmacokinetic Properties of Memantine after a Single Intraperitoneal Administration and Multiple Oral Doses in Euploid Mice and in the Ts65Dn Mouse Model of Down's Syndrome. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 382-389.	1.2	9
332	Management of glaucoma as a neurodegenerative disease. <i>Neurodegenerative Disease Management</i> , 2017, 7, 157-172.	1.2	32
333	Synaptopathic mechanisms of neurodegeneration and dementia: Insights from Huntington's disease. <i>Progress in Neurobiology</i> , 2017, 153, 18-45.	2.8	52
334	Memantine and Ketamine Differentially Alter NMDA Receptor Desensitization. <i>Journal of Neuroscience</i> , 2017, 37, 9686-9704.	1.7	57
335	Incorporation of dihydroartemisinin into memantine through a propiate spacer to make hybrid with enhanced effects to protect PC12 cells from corticosterone-caused impairments. <i>Chemical Research in Chinese Universities</i> , 2017, 33, 611-622.	1.3	3
336	Can an FDA-Approved Alzheimer's Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?. <i>MBio</i> , 2017, 8, .	1.8	11
338	NMDA receptor antagonist prevents cell death in the hippocampal dentate gyrus induced by hyponatremia accompanying adrenal insufficiency in rats. <i>Experimental Neurology</i> , 2017, 287, 65-74.	2.0	8
339	Generalized reduced rank latent factor regression for high dimensional tensor fields, and neuroimaging-genetic applications. <i>NeuroImage</i> , 2017, 144, 35-57.	2.1	9
340	Enhanced LTP in aged rats: Detrimental or compensatory?. <i>Neuropharmacology</i> , 2017, 114, 12-19.	2.0	25
341	Enhancing Effects of NMDA-Receptor Blockade on Extinction Learning and Related Brain Activation Are Modulated by BMI. <i>Frontiers in Behavioral Neuroscience</i> , 2017, 11, 34.	1.0	4
342	Alpha7 Nicotinic Acetylcholine Receptors Play a Predominant Role in the Cholinergic Potentiation of N-Methyl-D-Aspartate Evoked Firing Responses of Hippocampal CA1 Pyramidal Cells. <i>Frontiers in Cellular Neuroscience</i> , 2017, 11, 271.	1.8	21
343	Efficacy of Memantine in Schizophrenic Patients: A Systematic Review. <i>Journal of Amino Acids</i> , 2017, 2017, 1-6.	5.8	25
344	Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson's disease treated with L-DOPA. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 449.	3.7	27
345	Excitotoxicity: An Organized Crime at The Cellular Level. <i>Journal of Neurology and Neuroscience</i> , 2017, 08, .	0.4	14
346	Amaryllidaceae alkaloids as agents with protective effects against oxidative neural cell injury. <i>Life Sciences</i> , 2018, 203, 54-65.	2.0	21
347	Chemo-Biocatalytic Oxidative Condensation of Natural Arylpropene with 2-Aminobenzothiazole into Schiff-Bases as Potent Anti-Amyloid Agents: Studies Employing Transgenic <i>C. elegans</i> . <i>ChemistrySelect</i> , 2018, 3, 3539-3547.	0.7	2
348	Excitotoxicity in the pathogenesis of neurological and psychiatric disorders: Therapeutic implications. <i>Journal of Psychopharmacology</i> , 2018, 32, 265-275.	2.0	136

#	ARTICLE	IF	CITATIONS
349	A facile tandem double-dehydrative-double-Heck olefination strategy for pot-economic synthesis of (E) Tj ETQq0 0 0 rgBT /Overlock 10 T model. Tetrahedron, 2018, 74, 1655-1667.	1.0	6
350	Psychotomimetic-like behavioral effects of memantine in the mouse. Biomedicine and Pharmacotherapy, 2018, 100, 116-123.	2.5	9
351	The role of memantine in the treatment of major depressive disorder: Clinical efficacy and mechanisms of action. European Journal of Pharmacology, 2018, 827, 103-111.	1.7	35
352	Memantine decreases neuronal degeneration in young rats submitted to LiCl-pilocarpine-induced status epilepticus. NeuroToxicology, 2018, 66, 45-52.	1.4	10
353	Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3007-E3016.	3.3	160
354	Cognitive changes under memantine according to vitamin D status in Alzheimer patients: An exposed/unexposed cohort pilot study. Journal of Steroid Biochemistry and Molecular Biology, 2018, 175, 151-156.	1.2	18
355	Are you a doctor? â€ <i>Are you a doctor? lâ€™m not a doctor!</i> A reappraisal of mitigated echolalia in aphasia with evaluation of neural correlates and treatment approaches. Aphasiology, 2018, 32, 784-813.	1.4	9
356	Syntheses, analytical and pharmacological characterizations of the â€legal highâ€™ 4â€[1â€(3â€methoxyphenyl)cyclohexyl]morpholine (3â€MeOâ€PCMo) and analogues. Drug Testing and Analysis, 2018, 10, 272-283.	1.6	13
357	Brain Under Stress and Alzheimerâ€™s Disease. Cellular and Molecular Neurobiology, 2018, 38, 73-84.	1.7	32
358	A Systematic Review of NMDA Receptor Antagonists for Treatment of Neuropathic Pain in Clinical Practice. Clinical Journal of Pain, 2018, 34, 450-467.	0.8	98
359	Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2018, 32, 3-29.	2.0	196
360	Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease. Journal of Ethnopharmacology, 2018, 215, 42-73.	2.0	105
361	Magnesium boosts the memory restorative effect of environmental enrichment in Alzheimer's disease mice. CNS Neuroscience and Therapeutics, 2018, 24, 70-79.	1.9	32
362	Engaging homeostatic plasticity to treat depression. Molecular Psychiatry, 2018, 23, 26-35.	4.1	39
363	Medial septum modulates hippocampal gamma activity and prepulse inhibition in an N-methyl-d-aspartate receptor antagonist model of schizophrenia. Schizophrenia Research, 2018, 198, 36-44.	1.1	21
364	Bioprinting neural tissues using stem cells as a tool for screening drug targets for Alzheimerâ€™s disease. Journal of 3D Printing in Medicine, 2018, 2, 163-165.	1.0	6
365	Synthesis of Chromoneâ€Containing Allylmorpholines through a Moritaâ€Baylisâ€Hillmanâ€™Type Reaction. European Journal of Organic Chemistry, 2018, 2018, 6304-6313.	1.2	12
366	Donepezil structure-based hybrids as potential multifunctional anti-Alzheimerâ€™s drug candidates. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 1212-1224.	2.5	60

#	ARTICLE	IF	CITATIONS
367	The Use of Polyphenols for the Treatment of Alzheimer's Disease. , 2018, , 239-252.		4
368	Inhibition of NMDA Receptors Prevents the Loss of BDNF Function Induced by Amyloid β . <i>Frontiers in Pharmacology</i> , 2018, 9, 237.	1.6	54
369	Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer's Disease, and Parkinson's Disease. <i>Frontiers in Psychiatry</i> , 2018, 9, 91.	1.3	40
370	Memantine ameliorates depressive-like behaviors by regulating hippocampal cell proliferation and neuroprotection in olfactory bulbectomized mice. <i>Neuropharmacology</i> , 2018, 137, 141-155.	2.0	47
371	Effects of Mg ²⁺ on recovery of NMDA receptors from inhibition by memantine and ketamine reveal properties of a second site. <i>Neuropharmacology</i> , 2018, 137, 344-358.	2.0	19
372	The NMDA receptor antagonist Radiprodil reverses the synaptotoxic effects of different amyloid-beta (A β) species on long-term potentiation (LTP). <i>Neuropharmacology</i> , 2018, 140, 184-192.	2.0	22
373	An update on NMDA antagonists in depression. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1055-1067.	1.4	39
374	Psychotropic and neurological medication effects on mitochondrial complex I and IV in rodent models. <i>European Neuropsychopharmacology</i> , 2019, 29, 986-1002.	0.3	11
375	Toward higher extraction and enrichment factors via a double-reservoirs microfluidic device as a micro-extractive platform. <i>Journal of Separation Science</i> , 2019, 42, 2985-2992.	1.3	3
376	Temporal Lobe Cavernous Malformation Caused Epileptic Amnesic Episodes and Mild Cognitive Impairment. <i>Frontiers in Neurology</i> , 2019, 10, 620.	1.1	1
377	Facilitation and inhibition of firing activity and N-methyl-D-aspartate-evoked responses of CA1 hippocampal pyramidal cells by alpha7 nicotinic acetylcholine receptor selective compounds in vivo. <i>Scientific Reports</i> , 2019, 9, 9324.	1.6	10
378	Probiotic treatment improves the impaired spatial cognitive performance and restores synaptic plasticity in an animal model of Alzheimer's disease. <i>Behavioural Brain Research</i> , 2019, 376, 112183.	1.2	88
379	Medicines management for people with dementia. <i>Nursing Standard (Royal College of Nursing (Great Tj ETQq0 0 0 rgBT /Overlock 10 T</i>	0.1	3
380	Comorbid HIV infection and alcohol use disorders: Converging glutamatergic and dopaminergic mechanisms underlying neurocognitive dysfunction. <i>Brain Research</i> , 2019, 1723, 146390.	1.1	6
381	The Concentration of Memantine in the Cerebrospinal Fluid of Alzheimer's Disease Patients and Its Consequence to Oxidative Stress Biomarkers. <i>Frontiers in Pharmacology</i> , 2019, 10, 943.	1.6	13
382	Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 72, S145-S176.	1.2	26
383	Obesity as a Risk Factor for Alzheimer's Disease: Implication of Leptin and Glutamate. <i>Frontiers in Neuroscience</i> , 2019, 13, 508.	1.4	52
384	Amyloid Beta-Related Alterations to Glutamate Signaling Dynamics During Alzheimer's Disease Progression. <i>ASN Neuro</i> , 2019, 11, 175909141985554.	1.5	77

#	ARTICLE	IF	CITATIONS
385	Pharmacoeugenetics of Memantine in Dementia. , 2019, , 827-835.		0
386	A metabolic perspective of late onset Alzheimer's disease. Pharmacological Research, 2019, 145, 104255.	3.1	19
387	A therapeutic dose of memantine improves the performance of rats in an active place avoidance task under the continuous dissociation of distal room and proximal arena cues. Neurobiology of Learning and Memory, 2019, 162, 59-66.	1.0	3
388	N-Methyl-D-aspartate receptor open-channel blockers memantine and magnesium modulate nociceptive trigeminovascular neurotransmission in rats. European Journal of Neuroscience, 2019, 50, 2847-2859.	1.2	15
389	Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies. Autism, 2019, 23, 2096-2111.	2.4	31
390	LY379268 Does Not Have Long-Term Procognitive Effects nor Attenuate Glutamatergic Signaling in A β PP/PS1 Mice. Journal of Alzheimer's Disease, 2019, 68, 1193-1209.	1.2	10
391	The Effects of Acupuncture on Glutamatergic Neurotransmission in Depression, Anxiety, Schizophrenia, and Alzheimer's Disease: A Review of the Literature. Frontiers in Psychiatry, 2019, 10, 14.	1.3	61
392	Long-Term NMDAR Antagonism Correlates Weight Loss With Less Eating. Frontiers in Psychiatry, 2019, 10, 15.	1.3	9
393	Insights into the Potential Role of Mercury in Alzheimer's Disease. Journal of Molecular Neuroscience, 2019, 67, 511-533.	1.1	31
394	Potential Pharmacokinetic Drug-Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-D-Aspartate Receptor Antagonist. Molecules, 2019, 24, 1430.	1.7	5
395	The anaesthetic xenon partially restores an amyloid beta-induced impairment in murine hippocampal synaptic plasticity. Neuropharmacology, 2019, 151, 21-32.	2.0	7
396	The Role of NMDA Receptors in Alzheimer's Disease. Frontiers in Neuroscience, 2019, 13, 43.	1.4	275
397	Cognitive Enhancer Effects of Low Memantine Doses Are Facilitated by an Alpha7 Nicotinic Acetylcholine Receptor Agonist in Scopolamine-Induced Amnesia in Rats. Frontiers in Pharmacology, 2019, 10, 73.	1.6	19
398	The Role of the N-Methyl-D-Aspartate Receptors in Social Behavior in Rodents. International Journal of Molecular Sciences, 2019, 20, 5599.	1.8	16
399	Pharmacological Interventions to Enhance Stroke Recovery. , 2019, , 185-197.		0
400	Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies. Progress in Neurobiology, 2019, 174, 53-89.	2.8	223
401	Diet-induced insulin resistance elevates hippocampal glutamate as well as VGLUT1 and GFAP expression in A β PP/PS1 mice. Journal of Neurochemistry, 2019, 148, 219-237.	2.1	42
402	Disease-Modification in Huntington's Disease: Moving Away from a Single-Target Approach. Journal of Huntington's Disease, 2019, 8, 9-22.	0.9	3

#	ARTICLE	IF	CITATIONS
403	Down syndrome: Neurobiological alterations and therapeutic targets. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 98, 234-255.	2.9	63
404	Memantine can relieve the neuronal impairment caused by neurotropic virus infection. <i>Journal of Medical Virology</i> , 2019, 91, 935-940.	2.5	8
405	Memantine protects thalamocortical hyperexcitability-induced glutamatergic transmission by NMDA receptor antagonism via activation of system xc ⁻ . <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00457.	1.1	44
406	Nanoengineered biomaterial for brain tissue reconstruction and functional repairment. , 2019, , 145-166.		3
407	Daily memantine treatment blunts hedonic response to sucrose in rats. <i>Psychopharmacology</i> , 2020, 237, 103-114.	1.5	3
408	Memantine as Adjunctive Therapy in a Patient With Anti-N-Methyl-d-Aspartate Receptor Encephalitis. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 92-93.	0.7	5
409	Is cannabidiol a drug acting on unconventional targets to control drug-resistant epilepsy?. <i>Epilepsia Open</i> , 2020, 5, 36-49.	1.3	18
410	A Paradigmatic Case of Postselective Serotonin Reuptake Inhibitors Sexual Dysfunction or Withdrawal After Discontinuation of Selective Serotonin Reuptake Inhibitors?. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 93-95.	0.7	4
411	Memantine effects on ingestion microstructure and the effect of administration time: A within-subject study. <i>PLoS ONE</i> , 2020, 15, e0239270.	1.1	1
412	Hydrolytic Stability of New Amino Acids Analogues of Memantine. <i>Scientia Pharmaceutica</i> , 2020, 88, 38.	0.7	0
413	Neuroinflammation. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2020, 175, 235-259.	1.0	21
414	The Dual Role of Glutamatergic Neurotransmission in Alzheimer's Disease: From Pathophysiology to Pharmacotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7452.	1.8	63
415	LTP-like plasticity is impaired in amyloid-positive amnesic MCI but independent of PET-amyloid burden. <i>Neurobiology of Aging</i> , 2020, 96, 109-116.	1.5	14
416	Metabolome Changes in Cerebral Ischemia. <i>Cells</i> , 2020, 9, 1630.	1.8	79
417	In Vivo Plasticity at Hippocampal Schaffer Collateral-CA1 Synapses: Replicability of the LTP Response and Pharmacology in the Long-Evans Rat. <i>Neural Plasticity</i> , 2020, 2020, 1-24.	1.0	7
418	Interplay between Gating and Block of Ligand-Gated Ion Channels. <i>Brain Sciences</i> , 2020, 10, 928.	1.1	7
419	Synthetic analogues of memantine as neuroprotective and influenza viral inhibitors: in vitro and physicochemical studies. <i>Amino Acids</i> , 2020, 52, 1559-1580.	1.2	8
420	The A β ² aggregation modulator MRZ-99030 prevents and even reverses synaptotoxic effects of A β ¹⁻⁴² on LTP even following serial dilution to a 500:1 stoichiometric excess of A β ¹⁻⁴² , suggesting a beneficial prion-like seeding mechanism. <i>Neuropharmacology</i> , 2020, 179, 108267.	2.0	5

#	ARTICLE	IF	CITATIONS
421	Reduction of advanced tau-mediated memory deficits by the MAP kinase p38 ^β . <i>Acta Neuropathologica</i> , 2020, 140, 279-294.	3.9	24
422	The P2X7 Receptor: Central Hub of Brain Diseases. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 124.	1.4	87
423	Is Memantine Effective as an NMDA Receptor Antagonist in Adjunctive Therapy for Schizophrenia?. <i>Biomolecules</i> , 2020, 10, 1134.	1.8	13
424	Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders. <i>Journal of Neuroinflammation</i> , 2020, 17, 236.	3.1	19
425	Effects of haloperidol inhalation on MK-801- and memantine-induced locomotion in mice. <i>Libyan Journal of Medicine</i> , 2020, 15, 1808361.	0.8	3
426	Hippocampal alterations in glutamatergic signaling during amyloid progression in A ^β 2PP/PS1 mice. <i>Scientific Reports</i> , 2020, 10, 14503.	1.6	23
427	Overview of <i>Salvia miltiorrhiza</i> as a Potential Therapeutic Agent for Various Diseases: An Update on Efficacy and Mechanisms of Action. <i>Antioxidants</i> , 2020, 9, 857.	2.2	50
428	Toward refining Alzheimer's disease into overlapping subgroups. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12070.	1.8	7
429	Experimental Evidence of the Benefits of Acupuncture for Alzheimer's Disease: An Updated Review. <i>Frontiers in Neuroscience</i> , 2020, 14, 549772.	1.4	24
430	Adenosine A2A Receptor Antagonists Affects NMDA Glutamate Receptor Function. Potential to Address Neurodegeneration in Alzheimer's Disease. <i>Cells</i> , 2020, 9, 1075.	1.8	36
431	Guanosine fast onset antidepressant-like effects in the olfactory bulbectomy mice model. <i>Scientific Reports</i> , 2020, 10, 8429.	1.6	18
432	GSK-3 ^β regulates the synaptic expression of NMDA receptors via phosphorylation of phosphatidylinositol 4 kinase type III ^α . <i>European Journal of Neuroscience</i> , 2021, 54, 6815-6825.	1.2	11
433	Effects of ketamine and other rapidly acting antidepressants on hippocampal excitatory and inhibitory transmission. <i>Advances in Pharmacology</i> , 2020, 89, 3-41.	1.2	9
434	Effects of neural stem cell transplantation in Alzheimer's disease models. <i>Journal of Biomedical Science</i> , 2020, 27, 29.	2.6	54
435	Novel Anti-Alzheimer's Therapeutic Molecules Targeting Amyloid Precursor Protein Processing. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-19.	1.9	40
436	Synaptic input to brain tumors: clinical implications. <i>Neuro-Oncology</i> , 2021, 23, 23-33.	0.6	48
437	A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy. <i>Medicinal Research Reviews</i> , 2021, 41, 2689-2745.	5.0	26
438	Riluzole attenuates glutamatergic tone and cognitive decline in A ^β 2PP/PS1 mice. <i>Journal of Neurochemistry</i> , 2021, 156, 513-523.	2.1	25

#	ARTICLE	IF	CITATIONS
439	Chronic Memantine Treatment Ameliorates Behavioral Deficits, Neuron Loss, and Impaired Neurogenesis in a Model of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2021, 58, 204-216.	1.9	22
440	Hippocampal Degeneration and Behavioral Impairment During Alzheimer-Like Pathogenesis Involves Glutamate Excitotoxicity. <i>Journal of Molecular Neuroscience</i> , 2021, 71, 1205-1220.	1.1	19
441	Adjunctive Approaches to Aphasia Rehabilitation: A Review on Efficacy and Safety. <i>Brain Sciences</i> , 2021, 11, 41.	1.1	20
442	Potential involvement of perineuronal nets in brain aging. , 2021, , 163-172.		0
443	Anti-dementia Medication. , 2021, , 73-104.		0
445	Astrocytes respond to a neurotoxic A β 2 fragment with state-dependent Ca ²⁺ alteration and multiphasic transmitter release. <i>Acta Neuropathologica Communications</i> , 2021, 9, 44.	2.4	15
446	Molecular Factors Mediating Neural Cell Plasticity Changes in Dementia Brain Diseases. <i>Neural Plasticity</i> , 2021, 2021, 1-20.	1.0	13
447	Chemical similarity assisted search for acetylcholinesterase inhibitors: Molecular modeling and evaluation of their neuroprotective properties. <i>International Journal of Biological Macromolecules</i> , 2021, 174, 466-476.	3.6	8
448	Specific pathogenic mutations in the M3 domain of the GluN1 subunit regulate the surface delivery and pharmacological sensitivity of NMDA receptors. <i>Neuropharmacology</i> , 2021, 189, 108528.	2.0	9
449	Memantine ameliorates cognitive deficit in AD mice via enhancement of entorhinal CA1 projection. <i>BMC Neuroscience</i> , 2021, 22, 41.	0.8	8
451	Homocysteine and Age-Related Central Nervous System Diseases: Role of Inflammation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6259.	1.8	19
452	A review on advances of treatment modalities for Alzheimer's disease. <i>Life Sciences</i> , 2021, 276, 119129.	2.0	85
453	The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 654931.	1.7	67
454	Copper, Iron, Selenium and Lipo-Glycemic Dysmetabolism in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9461.	1.8	30
455	Potential of cognitive enhancer effects of Alzheimer's disease medication memantine by alpha7 nicotinic acetylcholine receptor agonist PHA-543613 in the Morris water maze task. <i>Psychopharmacology</i> , 2021, 238, 3273-3281.	1.5	13
456	Positive allosteric modulation of NMDA receptors: mechanisms, physiological impact and therapeutic potential. <i>Journal of Physiology</i> , 2022, 600, 233-259.	1.3	30
457	Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside. <i>Metabolic Brain Disease</i> , 2021, 36, 1591-1626.	1.4	65
458	Metallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimer's disease: Limitations, and current and future perspectives. <i>Journal of Trace Elements in Medicine and Biology</i> , 2021, 67, 126779.	1.5	60

#	ARTICLE	IF	CITATIONS
459	A tribute to Chris Parsons. <i>Neuropharmacology</i> , 2021, 195, 108633.	2.0	2
460	Reproduction-Associated Hormones and Adult Hippocampal Neurogenesis. <i>Neural Plasticity</i> , 2021, 2021, 1-20.	1.0	7
461	Structural exploration of multifunctional monoamine oxidase B inhibitors as potential drug candidates against Alzheimer's disease. <i>Bioorganic Chemistry</i> , 2021, 114, 105070.	2.0	17
462	Memantine exerts neuroprotective effects by modulating $\hat{\alpha}$ -synuclein transmission in a parkinsonian model. <i>Experimental Neurology</i> , 2021, 344, 113810.	2.0	8
463	Pharmacological Treatment of Autism. , 2010, , 245-267.		5
464	Pharmacological Treatment of Post-stroke Cognitive Deficits. , 2020, , 465-500.		5
465	Crystal structure of memantine's carboxyborane. <i>Acta Crystallographica Section E: Crystallographic Communications</i> , 2019, 75, 543-546.	0.2	1
466	Random mutagenesis of human serine racemase reveals residues important for the enzymatic activity. <i>Collection of Czechoslovak Chemical Communications</i> , 2010, 75, 59-79.	1.0	3
467	Anti-N-Methyl-D-Aspartic Acid Receptor 2 (Anti-NR2) Antibody in Neuropsychiatric Lupus Serum Damages the Blood-Brain Barrier and Enters the Brain. <i>Medical Science Monitor</i> , 2019, 25, 532-539.	0.5	10
468	Blockade of Gap Junction Hemichannel Suppresses Disease Progression in Mouse Models of Amyotrophic Lateral Sclerosis and Alzheimer's Disease. <i>PLoS ONE</i> , 2011, 6, e21108.	1.1	126
469	Efficacy of Memantine in Treating Patients with Dementia and Fibromyalgia. <i>Journal of Neurology & Stroke</i> , 2015, 3, .	0.0	1
470	Combination Drug Therapy for the Treatment of Alzheimer's Disease. <i>European Neurological Review</i> , 2012, 7, 92.	0.5	5
471	Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction. <i>Oncotarget</i> , 2016, 7, 55840-55862.	0.8	66
472	Memory-Enhancing Drugs: A Molecular Perspective. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 769-781.	1.1	8
473	NMDA Receptors in Glial Cells: Pending Questions. <i>Current Neuropharmacology</i> , 2013, 11, 250-262.	1.4	77
474	Memantine and Kynurenic Acid: Current Neuropharmacological Aspects. <i>Current Neuropharmacology</i> , 2016, 14, 200-209.	1.4	38
475	Therapeutic Perspectives of Drugs Targeting Toll-Like Receptors Based on Immune Physiopathology Theory of Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 909-920.	0.8	8
476	Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?. <i>The Open Neurology Journal</i> , 2009, 3, 27-44.	0.4	7

#	ARTICLE	IF	CITATIONS
477	Targeting Dopamine in Acute Traumatic Brain Injury. <i>The Open Drug Discovery Journal</i> , 2010, 2, 119-128.	0.8	30
478	Glutamate Modulators in the Treatment of Obsessive-Compulsive Disorder. <i>Psychiatric Annals</i> , 2015, 45, 308-315.	0.1	28
479	Chronic pre-treatment with memantine prevents amyloid-beta protein-mediated long-term potentiation disruption. <i>Neural Regeneration Research</i> , 2013, 8, 49-55.	1.6	2
480	Alzheimer's disease: An alternative approach. <i>Indian Journal of Medical Research</i> , 2017, 145, 723.	0.4	12
481	Activated Caspase-3 and Neurodegeneration and Synaptic Plasticity in Alzheimer's Disease. <i>Advances in Alzheimer's Disease</i> , 2015, 04, 63-77.	0.3	12
483	Clozapine augmentation strategies. <i>Mental Health Clinician</i> , 2019, 9, 336-348.	0.5	15
484	Upregulated NMDAR-enhanced GABAergic transmission underlies autistic-like deficits in <i>Htr3a</i> knockout mice. <i>Theranostics</i> , 2021, 11, 9296-9310.	4.6	12
485	Protective effect and mechanism of docosahexaenoic acid on the cognitive function in female APP/PS1 mice. <i>Food and Function</i> , 2021, 12, 11435-11448.	2.1	8
486	Mechanistic Aspects of Apiaceae Family Spices in Ameliorating Alzheimer's Disease. <i>Antioxidants</i> , 2021, 10, 1571.	2.2	8
487	Current Anti-Dementia Drugs: Hypothesis and Clinical Benefits. , 2009, , 237-241.		1
488	Neurochemical Aspects of Neurodegenerative Diseases. , 2010, , 249-324.		0
489	Presenilin-Based Transgenic Models of Alzheimer's Dementia. <i>Neuromethods</i> , 2011, , 415-437.	0.2	0
491	Memantine (Namenda). , 2011, , 184-192.		0
492	Metabolism, Roles, and Involvement of Lyso-glycerophospholipids in Neurological Disorders. , 2011, , 73-105.		0
493	Neuromodulators and its combinations for the preventive treatment of migraine. <i>Headache Medicine</i> , 0, , 173-181.	0.1	0
494	Bis(12)-Hupyridone, a Promising Multi-Functional Anti-Alzheimer's Dimer Derived from Chinese Medicine. , 0, , .		0
495	Roles for NF- κ B in Regulating Gene Expression in Synaptic Plasticity and Memory. , 2012, , 66-78.		0
496	Animal Models of Viral Encephalitis. , 2013, , 143-165.		0

#	ARTICLE	IF	CITATIONS
497	Pharmacotherapy to Improve the Acquired Aphasia following Brain Damages: A Review Study. Iranian Journal of Neurosurgery, 2015, 1, 10-16.	0.0	2
498	Practical Pharmacology of Memantine. , 2016, , 105-117.		0
499	Phenomenon of Excitotoxicity as the Object of Pharmacologic Effect in Dementia. International Neurological Journal, 2016, .	0.2	0
500	Drug Treatments of Dementia. The Japanese Journal of Rehabilitation Medicine, 2018, 55, 643-647.	0.0	1
501	Medicines management for people with dementia. Nursing Standard (Royal College of Nursing (Great Tj ETQq0 0 0 rgBT /Overlock 10 T	0.1	0
503	Dementia and usage of N-methyl-d-aspartate receptor antagonists. , 2020, , 573-584.		0
504	N-Methyl-D-Aspartate (NMDA) Receptor Antagonistic Effect and Ginsenoside Content of Panax ginseng C. A. Meyer Cultivar Root Extracts. Korean Journal of Medicinal Crop Science, 2020, 28, 9-20.	0.1	2
505	Glutamate and GABA in Microglia-Neuron Cross-Talk in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 11677.	1.8	54
506	Adverse Drug Reactions, Intoxications and Interactions of Neuropsychotropic Medications. , 2020, , 1-53.		0
507	Morpholine derivatives as potential agents for neurological manifestations of nervous system diseases. Pharmacy Formulas, 2020, 2, 16-35.	0.2	3
508	Progress in the development of new drugs in Alzheimerâ€™s disease. Journal of Nutrition, Health and Aging, 0, , .	1.5	0
509	Relative tolerability of Alzheimer's disease treatments. Psychiatry, 2008, 5, 27-36.	0.3	16
510	Multi-level control of ionotropic glutamate receptor function. Cellscience, 2009, 6, 79.	0.3	0
511	Can zebrafish be used as animal model to study Alzheimer's disease?. American Journal of Neurodegenerative Disease, 2012, 1, 32-48.	0.1	22
513	Tolerability and Efficacy of Memantine as Add on Therapy in Patients with Migraine. Iranian Journal of Pharmaceutical Research, 2017, 16, 791-797.	0.3	7
514	Deficits in N-Methyl-D-Aspartate Receptor Function and Synaptic Plasticity in Hippocampal CA1 in APP/PS1 Mouse Model of Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 772980.	1.7	19
515	Deficient neurotransmitter systems and synaptic function in frontotemporal lobar degenerationâ€™Insights into disease mechanisms and current therapeutic approaches. Molecular Psychiatry, 2022, 27, 1300-1309.	4.1	17
516	Better language through chemistry: Augmenting speech-language therapy with pharmacotherapy in the treatment of aphasia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2022, 185, 261-272.	1.0	10

#	ARTICLE	IF	CITATIONS
517	Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Neurology</i> , The, 2022, 21, 31-41.	4.9	13
518	Recent developments in the management of Huntington's disease. <i>Bioorganic Chemistry</i> , 2022, 120, 105642.	2.0	11
519	Poststroke Aphasia Treatment. <i>The Journal of the International Society of Physical and Rehabilitation Medicine</i> , 2022, 5, 1-15.	0.1	1
520	Challenges and Approaches of Drugs Such as Memantine, Donepezil, Rivastigmine, and Aducanumab in the Treatment, Control and Management of Alzheimer's Disease. <i>Recent Patents on Biotechnology</i> , 2022, 16, 102-121.	0.4	13
521	The Computer Simulation of Therapy with the NMDA Antagonist in Excitotoxic Neurodegeneration in an Alzheimer's Disease-like Pathology. <i>Journal of Clinical Medicine</i> , 2022, 11, 1858.	1.0	8
522	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2022, 236, 114354.	2.6	10
523	Role of NMDA Receptors in Alzheimer's Disease Pathology and Potential NMDA Receptor Blockers from Medicinal Plants - A Review. <i>Asian Journal of Pharmaceutical Research and Health Care</i> , 2021, 13, 321.	0.0	0
526	Computational Modeling of Therapy with the NMDA Antagonist in Neurodegenerative Disease: Information Theory in the Mechanism of Action of Memantine. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4727.	1.2	5
536	NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer Disease. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, .	0.6	1
538	Infrared spectra and structures of protonated amantadine isomers: detection of ammonium and open-cage iminium ions. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 16101-16111.	1.3	2
539	Memantine as treatment for compulsivity in child and adolescent psychiatry: Descriptive findings from an incompleated randomized, double-blind, placebo-controlled trial. <i>Contemporary Clinical Trials Communications</i> , 2022, 29, 100982.	0.5	2
540	Suppression of exaggerated NMDAR activity by memantine treatment ameliorates neurological and behavioral deficits in aminopeptidase P1-deficient mice. <i>Experimental and Molecular Medicine</i> , 2022, 54, 1109-1124.	3.2	4
541	Recent developments in the synthesis of pyridine analogues as a potent anti-Alzheimer's therapeutic leads. , 2023, , 411-444.		1
542	Förster resonance energy transfer-based kinase mutation phenotyping reveals an aberrant facilitation of Ca ²⁺ /calmodulin-dependent CaMKII β activity in de novo mutations related to intellectual disability. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	1.4	1
543	Sanlarda Kronik uygulanan Timokinonun Penisilin ile Oluşturulmuş Epileptiform Aktivite Açzerine Etkileri. <i>Anadolu Kliniği Tıp Bilimleri Dergisi</i> , 0, , .	0.1	0
545	Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance. <i>Cancer Discovery</i> , 2023, 13, 170-193.	7.7	6
546	A narrative review of treatment interventions to improve cognitive performance in schizophrenia, with an emphasis on at-risk and early course stages. <i>Psychiatry Research</i> , 2022, 317, 114926.	1.7	1
547	Adverse Drug Reactions, Intoxications and Interactions of Neuropsychotropic Medications. , 2022, , 361-414.		0

#	ARTICLE	IF	CITATIONS
548	Marine Natural Products from the Russian Pacific as Sources of Drugs for Neurodegenerative Diseases. <i>Marine Drugs</i> , 2022, 20, 708.	2.2	8
549	A Review on Recent Development of Novel Heterocycles as Acetylcholinesterase Inhibitor for the Treatment of Alzheimer's Disease. <i>Current Drug Targets</i> , 2023, 24, 225-246.	1.0	4
550	Exploration of the potential neuroprotective compounds targeting GluN1-GluN2B NMDA receptors. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 10900-10908.	2.0	1
551	Role of Metal Cations of Copper, Iron, and Aluminum and Multifunctional Ligands in Alzheimer's Disease: Experimental and Computational Insights. <i>ACS Omega</i> , 2023, 8, 4508-4526.	1.6	10
552	Microhydrated clusters of a pharmaceutical drug: infrared spectra and structures of amantadine H_2O . <i>Physical Chemistry Chemical Physics</i> , 2023, 25, 5529-5549.	1.3	2
553	Comprehensive Bibliometric Analysis of Stem Cell Research in Alzheimer's Disease from 2004 to 2022. <i>Dementia and Geriatric Cognitive Disorders</i> , 2023, 52, 47-73.	0.7	10
555	The NMDA receptor antagonists memantine and ketamine as anti-migraine agents. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2023, 396, 1371-1398.	1.4	3
556	Memantine/Aripiprazole Combination Alleviates Cognitive Dysfunction in Valproic Acid Rat Model of Autism: Hippocampal CREB/BDNF Signaling and Glutamate Homeostasis. <i>Neurotherapeutics</i> , 2023, 20, 464-483.	2.1	8
557	Extract of <i>Aster koraiensis</i> Nakai Leaf Ameliorates Memory Dysfunction via Anti-inflammatory Action. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5765.	1.8	4
558	Stem cells in the treatment of Alzheimer's disease – Promises and pitfalls. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2023, 1869, 166712.	1.8	1
571	The Glutamatergic Hypothesis of Alzheimer's Disease. , 2023, , 93-107.		1
574	Deciphering New Drug Targets in Alzheimer's Disease. , 2023, , 1-18.		0
575	Cytosolic phospholipase A2 (cPLA2)-mediated oxidative and inflammatory responses in neurodegenerative diseases. , 2023, , 79-90.		0
589	Metal Chelators as a Potential Therapeutic Agent for Alzheimer's Disease. , 2023, , 347-374.		0